Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

siemens d.d., zagreb - ultrazvučni uređaji

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

glaxosmithkline d.o.o.sarajevo - cefuroksim - prašak za rastvor za injekciju ili infuziju - 750 mg/1 viala - 1 bočica praška za rastvor za injekciju ili infuziju sadrži: 750 mg cefuroksima (u obliku cefuroksim natrijuma)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

glaxosmithkline d.o.o.sarajevo - cefuroksim - prašak za rastvor za injekciju ili infuziju - 1.5 g/1 viala - 1 bočica sa praškom za rastvor za injekciju ili infuziju sadrži: 1,5 g cefuroksima (u obliku cefuroksim natrijuma)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

glaxosmithkline d.o.o.sarajevo - papilomavirus (humanitarne tipovi 16, 18) - suspenzija za injekciju u napunjenoj šprici - 20 µg/0.5 ml+ 20 µg/0.5 ml - 0,5 ml suspenzije za injekciju u napunjenoj šprici (1 doza) sadrži: 20 mcg humanog papiloma virusa tipa 16 l1 (vlp) 20 mcg humanog papiloma virusa tipa 18 l1 (vlp)

Europska Unija - hrvatski - EMA (European Medicines Agency)

bayer animal health gmbh - имидаклоприд, моксидектин - antiparazitski proizvodi, insekticidi i repelenti - dogs; cats; ferrets - dogsfor psi koji pate od ili sklone, mješoviti parazitskih infekcija:prevencija i liječenje invazija buha (ctenocephalides feliz),liječenje ugriza uši (trichodectes velikog psa),liječenje ушного grinje infestacije (otodectes cynotis), саркоптозе (uzrokovane sarcoptes bolesti opcije. velikog psa), demodectic šuge (uzrokovane демодекс канис),prevenciju srčanog crva bolesti (l3 i l4 larve srčani crvi),liječenje kruži микрофилярии (srčane crve),za liječenje kožnih dirofilariosis (stadija zrelih дирофилярий repens)prevenciju kožnih dirofilariosis (Л3 ličinke дирофилярий repens),smanjenje kruži микрофилярии (srčane repens),prevencija angiostrongylosis (Л4 ličinke i nezreli odrasli angiostrongylus vasorum),liječenje angiostrongylus vasorum i crenosoma vulpis,prevencija spirocercosis (spirocerca лупи),liječenje eucoleus (suen. capillaria) boehmi (odrasli),liječenje oka crva thelazia callipaeda (odrasli),za liječenje infekcija probavnog trakta hookworms (Л4 larve, nezreli odrasli i odrasli Тохосага canis, ancylostoma сатпит i uncinaria stenocephala, imago toxascaris leonina i trichuris vulpis). proizvod se može koristiti kao dio strategije liječenja alergije dermatitisa buha (fad). catsfor mačke pate od ili sklone, mješoviti parazitskih infekcija:prevencija i liječenje invazija buha (ctenocephalides feliz),liječenje ушного grinje infestacije (otodectes cynotis),liječenje notoedric mangan (notoedres cati u),liječenje lungworm eucoleus aerophilus (suen. capillaria aerophila) (za odrasle),prevenciji bolesti lungworm (Л3/Л4 larve aelurostrongylus abstrusus),liječenje lungworm aelurostrongylus abstrusus (odrasli),liječenje oka crva thelazia callipaeda (odrasli),za prevenciju srčanog crva bolesti (l3 i l4 larve srčani crvi),za liječenje infekcija probavnog trakta hookworms (Л4 larve, nezreli odrasli i odrasli Тохосага cati i infestacije ancylostoma tubaeforme). proizvod se može koristiti kao dio strategije liječenja alergije dermatitisa buha (fad). ferretsfor prekapati, pate od ili sklone, mješoviti parazitskih infekcija:prevencija i liječenje invazija buha (ctenocephalides feliz),prevenciju srčanog crva bolesti (l3 i l4 ličinke srčani crvi).

Europska Unija - hrvatski - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakonazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimikotika za sustavnu uporabu - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 i 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 i 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Огнеупорность definira kao progresiju infekcije ili nedostatak poboljšanja nakon što je minimum 7 dana do terapijske doze učinkovit antifungalna terapija. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 i 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 i 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 i 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Огнеупорность definira kao progresiju infekcije ili nedostatak poboljšanja nakon što je minimum 7 dana do terapijske doze učinkovit antifungalna terapija. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 i 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 i 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Огнеупорность definira kao progresiju infekcije ili nedostatak poboljšanja nakon što je minimum 7 dana do terapijske doze učinkovit antifungalna terapija. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor. Огнеупорность definira kao progresiju infekcije ili nedostatak poboljšanja nakon što je minimum 7 dana do terapijske doze učinkovit antifungalna terapija. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

b.i.g. b.l.u.e. d.o.o. pina budicina 13 52100 pula -

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - živjeti аттенуированного virus infektivne бурсальной bolesti (ibdv), procijediti 1052 - imunomodulatori za ptice, domaće peradi, živa virusna cjepiva, ptica zaraznih бурсальной bolesti virus (bolest Гамборо) - chicken; embryonated chicken eggs - za aktivne imunizacije 1-dnevne pilića i эмбрионами tovnih jaja za smanjenje kliničkih manifestacija i gubitka фабрициевой torbi, nošena vrlo вирулентные ptica zaraznih бурсальной bolesti virusne infekcije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

orion corporation - tasipimidine sulfate - other hypnotics and sedatives - psi - alleviation of situational anxiety and fear in dogs triggered by e. travel, noise, owner departure, veterinary visits.

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - kapecitabin - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastična sredstva - kapecitabinski sporazum je indiciran za adjuvantno liječenje pacijenata nakon operacije stadija iii (dukes stage-c) raka debelog crijeva. Капецитабин pristanka indiciran za liječenje метастатического raka debelog crijeva . Капецитабин pristanka indiciran za prva linija terapije popularnog raka želuca u kombinaciji s platinum temelju stanja. akord капецитабином u kombinaciju sa docetaxel indiciran za liječenje bolesnika s lokalno-uobičajena ili metastatskih tumora dojke neučinkovitosti цитотоксической kemoterapije. prethodna terapija mora sadržavati антрациклиновый. Капецитабин sporazum je također navedeno kao monoterapija za liječenje bolesnika s lokalno-uobičajena ili metastatskih tumora dojke neučinkovitosti Таксанов i антрациклинов sadrže načina kemoterapije ili za koje antikancerogena terapija nije naveden.